타기관

Home > Community > 공지사항 > 타기관

Proteomonitor에 실린 YPRC 기사 내용.

작성자
KHUPO
조회
769
연락처
***-****-****
이메일
***********
작성일
2004.03.10. 13:45:43
첨부
volume 3, number 33 August 15, 2003 1 page , 5page As Pan-Asian Proteomics Powerhouse Emerges, Focus is on Liver Cancer, SARS IT MAY BE many time zones away from the headquarters of the big European and American companies, but Asia has become an emerging powerhouse in proteomics, with plenty of money to make and earn. Asian proteomics scientists have formed their own club . Asia-Oceania Human Proteome Organization; their own interest groups, particularly for the study of liver disease and of SARS; and their own international collaborations. And as big instrument companies like Waters have recently been discovering , the Asian market for proteomics equipment is set to explode (see PM 7-25-03). This past weekend, representatives from the eight member nations of AOHUPO held a teleconference to plan the group’s next meeting, which was postponed from its original September date due to SARS. Also, On Aug. 28, representatives from many countries in the region will meet in the North Asia Proteomics Conference, in Seoul, South Korea. ProteoMonitor talked this week with some of the big players from five major Asian proteomics centers about their work and about the peculiarities of Asian proteomics. YONSEI PROTEOME RESEARCH CENTER, SEOUL, SOUTH KOREA Researchers at the Yonsei Proteome Research Center, led by Young-Ki Paik, president of the regional KHUPO and secretarygeneral of HUPO, are conducting five major proteomics projects: proteome profile changes in cholesterol metabolism; proteome analysis of hepatocellular cancer (part of HUPO’s liver proteome project); proteome expression comparison of lung cancer tumors; the construction of a database for the liver cancer proteome; and, most recently, the initiation of the Korean Human Plasma Proteome Project (part of HUPO’s HPPP). At the moment, Paik is most excited about the KHPPP, for which his center just received an eight-year grant of $2.1 million per year from the Korean government. The project, which will receive guidance, protocols, and coordination from HUPO HPPP, began in July and represents a major breakthrough for proteomics funding in Korea, according to Paik. “This is the first time ever that the Korean government has put money on a global project like HPPP. The government usually puts money on something short term, like the development of drug targets, not on the construction of a reference map like this. This is a very meaningful start,” Paik said. The government is also currently funding “another wing” of proteomics projects focusing on drug development, to the tune of $4 million a year. In general, the Korean government is becoming more and more supportive of proteomics research, mostly as a way to balance out its already considerable generosity with genomics funding, according to Paik. Like just about every other proteomics center in Asia, Paik’s research also focuses on liver disease. the second major cause of cancer death in Korea, and a huge problem throughout Asia, where hepatitis B and C still run rampant. “Liver disease is an awfully important disease among Asians, so we are trying to focus on those type of diseases together and cooperate in some additional organizations and collaborations,” Paik said. Paik also is no stranger to the world of industrial collaborations. In addition to a partnership with a Korean private company that he did not name but said was providing his lab with $1 million over five years, Paik’s group also is managing a plethora of international industrial collaborations. Paik manages Korea’s Expasy mirror site for Swiss-Prot, and has worked extensively with GeneBio, creator of Melanie software (see PM 7-25-03). Paik claims to be the first person to train people to use Melanie 4.0, which was released in February as a beta product and will now be incorporated into Amersham’s 2D imaging software. He also said he is working with Nonlinear Dynamics to build up “a Progenesis type of database system.” In terms of instrument companies, Paik has built collaborations with Applied Biosystems and Agilent Technologies, and the latter will use Paik’s lab as a reference laboratory for its latest nano-ESI and tandem MS/MS products. Paik also has collaborations with Osaka University and Yamaguchi University in Japan. Most of these collaborations pay off in the form of additional funds for YPRC. Still, “funding is never, never enough,” Paik said. Paik will be the keynote speaker at the August conference in Seoul.
Total : 113개 (page : 8/8)
처음 페이지 이전 페이지 1 2 3 4 5 6 7 8 다음 페이지 마지막 페이지